Antisense oligonucleotide targeting circFOXK2 and application thereof

Through the combined treatment of antisense oligonucleotide targeting circFOXK2 and tamoxifen, the problems of cell cycle out-of-control and endocrine therapy resistance of ER-positive breast cancer were solved, and effective inhibition of ER-positive breast cancer cells was achieved and Recovery of sensitivity to endocrine therapy.

CN119082114APending Publication Date: 2024-12-06XIAMEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411496561.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-25
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to effectively target CCND1 mRNA, resulting in ER-positive breast cancer cell cycle out of control and drug resistance to endocrine therapy. The regulatory mechanism of targeting circRNA is still unclear.

Method used

Develop antisense oligonucleotides targeting circFOXK2, combined with tamoxifen to inhibit the growth of ER-positive breast cancer cells, and restore the cell pair by combining antisense oligonucleotides targeting circFOXK2 and tamoxifen. Tamoxifen sensitivity.

Benefits of technology

It can effectively inhibit the growth of ER-positive breast cancer cells in vivo and in vitro, restore the sensitivity of cells to tamoxifen, overcome the resistance to endocrine therapy, and significantly reduce the expression of CCND1 and the activity of E2F target genes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082114A_ABST
    Figure CN119082114A_ABST
Patent Text Reader

Abstract

The invention discloses antisense oligonucleotide targeting circFOXK2 and application of the antisense oligonucleotide. The nucleotide sequence of the antisense oligonucleotide is shown as SEQ ID NO. 34. The antisense oligonucleotide targeting circFOXK2 can inhibit the growth of ER positive breast cancer cells in vivo and in vitro, has a synergistic effect with tamoxifen, and can recover the sensitivity of tamoxifen drug-resistant positive breast cancer cells to tamoxifen.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of molecular biology, and specifically relates to an antisense oligonucleotide targeting circFOXK2 and a use thereof. Background Art

[0002] According to the latest global cancer statistics analysis, breast cancer remains the most common type of cancer and the leading cause of cancer death in women. About 70% of breast cancers are of the estrogen receptor-positive (ER-positive) subtype, and endocrine therapy is currently the first-line treatment for patients with ER-positive breast cancer. However, a considerable proportion of patients face primary or acquired drug resistance.

[0003] The CCND1 gene is a widely studied oncogene that encodes the G1 / S-specific cell cycle protein cyclin D1. It is generally believed that CCND1 forms a complex with CDK4 / 6 and phosphorylates the tumor suppressor retinoblastoma protein (RB), thereby inducing the release of the early G1 transcription factor E2Fs. E2F further activates a large number of E2F target genes and promotes the entry of cells into the S phase. Studies have shown that the reduction of CCND1 expression is an early and critical event in endocrine therapy. However, CCND1 overexpression is often observed in approximately 50% of breast cancers, of which approximately 15% are caused by gene amplification. In addition, other signaling pathways such as phosphoinositide kinase (PI3K) or post-transcriptional regulation can also drive CCND1 expression. Uncontrolled cell cycle progression caused by CCND1 overexpression is one of the main reasons for poor prognosis and endocrine therapy resistance in ER-positive breast cancer. Therefore, targeting CCND1 or combining endocrine therapy may be an effective strategy for the treatment of ER-positive breast cancer.

[0004] Circular RNAs (circRNAs) differ from other RNA species in that their 5' and 3' ends are covalently linked to form a closed loop structure, which makes them immune to endonuclease degradation. An increasing number of studies have shown that circRNAs are closely related to pathological processes and are of great significance in the diagnosis and treatment of diseases. RNA-RNA interactions between circRNAs and miRNAs are the most common mode of action of circRNAs. Previous studies have shown that circPVT1 promotes breast tumorigenesis and endocrine resistance in ER-positive breast cancer by acting as a competitive endogenous RNA (ceRNA) sponge to adsorb miR-181a-2-3p and stabilize ESR1 mRNA. Recent studies have shown that circZNF609 directly binds to CKAP5 mRNA and enhances the translation of CKAP5. However, it is still unclear whether CCND1 mRNA is regulated by circRNAs and whether targeting this circRNA can effectively inhibit the growth of ER-positive breast cancer cells and overcome endocrine therapy resistance. Summary of the invention

[0005] The present invention aims to provide an antisense oligonucleotide targeting circFOXK2.

[0006] Another object of the present invention is to provide uses of the antisense oligonucleotide.

[0007] The technical solution of the present invention is as follows:

[0008] An antisense oligonucleotide targeting circFOXK2, whose nucleotide sequence is shown in SEQ ID NO.34.

[0009] Use of the above antisense oligonucleotide in preparing a composition for inhibiting the growth of ER-positive breast cancer cells.

[0010] In a preferred embodiment of the present invention, the ER-positive breast cancer cell growth inhibitory composition further contains tamoxifen.

[0011] An ER-positive breast cancer cell growth inhibition composition, whose effective ingredients include the above-mentioned antisense oligonucleotide.

[0012] In a preferred embodiment of the present invention, the active ingredient further comprises tamoxifen.

[0013] Use of the above antisense oligonucleotide in preparing a composition for treating ER-positive breast cancer.

[0014] In a preferred embodiment of the present invention, the ER-positive breast cancer treatment composition further contains tamoxifen.

[0015] A composition for treating ER-positive breast cancer, the effective component of which includes the antisense oligonucleotide.

[0016] In a preferred embodiment of the present invention, the active ingredient further comprises tamoxifen.

[0017] Further preferably, the effective ingredients consist of the antisense oligonucleotide and tamoxifen.

[0018] The beneficial effects of the present invention are:

[0019] 1. The antisense oligonucleotides of the present invention target circFOXK2 and can inhibit the growth of ER-positive breast cancer cells both in vivo and in vitro.

[0020] 2. The antisense oligonucleotide of the present invention has a synergistic effect with tamoxifen and can restore the sensitivity of tamoxifen-resistant positive breast cancer cells to tamoxifen. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1It is shown that circFOXK2 in Example 1 of the present invention promotes the growth and tumor formation of ER-positive breast cancer cells. Wherein: (A) Sanger sequencing results of circFOXK2 splicing sites. D1: Primer 1; D2: Primer 2. (BD) MCF7 cells transfected with control siRNA (si-CTL) or two independent siRNAs specifically targeting circFOXK2 (si-circFOXK2-1 and si-circFOXK2-2) were subjected to RT-qPCR (B), cell proliferation (C) and flow cytometry (D) analysis (±SD, **P<0.01, ***P<0.001). (EG) MCF7 cells transfected with empty vector (EV) or circFOXK2-expressing vector were subjected to RT-qPCR (E), cell proliferation (F) and flow cytometry (G) analysis (±SD, ***P<0.001). (H) MCF7 cells infected with control shRNA (sh-CTL) or two independent shRNAs specifically targeting circFOXK2 (sh-circFOXK2-1 and sh-circFOXK2-2) were subjected to RT-qPCR (±SD, ***P<0.001). (IK) MCF7 cells infected with sh-CTL, sh-circFOXK2-1 or sh-circFOXK2-2 described in (H) were subcutaneously injected into female BALB / C nude mice for xenograft experiments. Growth curves (I), images (J), and weights (K) of tumors are shown (n=5, ±SD, **P<0.01, ***P<0.001).

[0022] Figure 2It is shown that CircFOXK2 in Example 1 of the present invention positively regulates the expression of CCND1, activates E2F target genes, and promotes G1 / S transition. Wherein: (A) MCF7 cells were transfected with control siRNA (si-CTL) or two circFOXK2-specific siRNAs (si-circFOXK2-1 and si-circFOXK2-2), and then RNA-seq analysis was performed. The effects of the two si-circFOXK2 on the entire transcriptome were correlated (Pearson correlation coefficient = 0.7717). (B) The volcano map shows the circFOXK2 positively regulated and negatively regulated genes based on RNA-seq analysis in (A) (FDR<0.05, FC≥1.5). (C) The figure shows the 5 most abundant GO terms of circFOXK2 positively regulated genes. (D) The UCSC visualization analysis results of CCND1 are displayed. (EG) RT-qPCR (E, G) and immunoblot (F) analysis of MCF7 cells transfected with si-CTL, si-circFOXK2-1 or si-circFOXK2-2 (±SD, *P<0.05, **P<0.01, ***P<0.001). Figure 1 RNA extraction and RT-qPCR analysis were performed on tumor samples shown in J (n=5, ±SD, *P<0.05, **P<0.01, ***P<0.001). (IK) Empty vector (EV) or vector expressing circFOXK2 was overexpressed in MCF7 cells transfected with si-CTL or si-circFOXK2, followed by RT-qPCR (I, K) and immunoblotting (J) analysis (±SD, *P<0.05, **P<0.01, ***P<0.001). (LO) EV or Flag-tagged CCND1 was overexpressed in MCF7 cells transfected with si-CTL or si-circFOXK2, followed by immunoblotting (L), RT-qPCR (M), flow cytometry (N) and cell proliferation (O) analysis (±SD, *P<0.05, **P<0.01, ***P<0.001).

[0023] Figure 3It shows that circFOXK2 in Example 1 of the present invention pairs with the 3'UTR of CCND1 mRNA and recruits ELAVL1 to stabilize CCND1 mRNA. Wherein: (A) MCF7 cells were subjected to nucleocytoplasmic separation, RNA extraction and RT-qPCR analysis. (B) After MCF7 cells were transfected with control siRNA (si-CTL) or two circFOXK2-specific siRNAs (si-circFOXK2-1 and si-circFOXK2-2), RNA-FISH analysis was performed using a probe specifically targeting circFOXK2. DAPI stains the nucleus. Green: circFOXK2; Blue: DAPI. Scale bar: 5 μm. (C) Schematic diagram of the predicted RNA-RNA interaction region between circFOXK2 and the 3'UTR of CCND1. (D) In ​​vitro RNA-RNA interaction assay in the presence or absence of the 3′UTR of CCND1 in the presence or absence of biotin-labeled sense circFOXK2 (circFOXK2-S), antisense circFOXK2 (circFOXK2-AS), or deletion of the predicted CCND1 binding region (circFOXK2(Δ120-217)-S). RT-qPCR analysis was performed using primers specifically targeting the 3′UTR of CCND1. Data were normalized to the amount of RNA extracted from empty magnetic beads. (±SD, **p<0.01, ***p<0.001). (E, F) Cell lysates prepared from MCF7 cells were incubated with sense (Junction-S) or antisense (Junction-AS) probes targeting the backsplicing site of circFOXK2, followed by RT-qPCR (E) and immunoblot (F) analysis (±SD, ns: not statistically significant, ***P<0.001). (G, H) Lysates of MCF7 cells transfected with si-CTL or si-circFOXK2 were incubated with control IgG or anti-ELAVL1 antibody, followed by immunoblotting (G) and RT-qPCR (H) analysis (±SD, ns: not statistically significant, *P<0.05, **P<0.01). (I) MCF7 cells were transfected with si-CTL or si-circFOXK2, and then treated with or without actinomycin D (ActD, 10 μg / mL) as indicated, followed by RT-qPCR analysis (±SD, *P<0.05, **P<0.01).(J, K) HEK293T cells were transfected with empty vector (EV) or vector expressing circFOXK2 (with or without Flag-tagged wild-type (WT) CCND1 or CCND1 lacking the circFOXK2 binding region (Δ2878-2963) in the 3'UTR) and analyzed by RT-qPCR (J) and immunoblotting (K) 48 h later (±SD, **P<0.01, ***P<0.001).

[0024] Figure 4 The antisense oligonucleotide (ASO) against circFOXK2 in Example 1 of the present invention inhibits the growth and tumor formation of ER-positive breast cancer cells. Wherein: (AE) MCF7 cells transfected with control ASO (ASO-CTL) or ASO specifically targeting circFOXK2 (ASO-circFOXK2) were subjected to RT-qPCR (A, C), immunoblotting (B), flow cytometry (D) and cell proliferation (E) analysis (±SD, *P<0.05, **P<0.01, ***P<0.001). (FH) MCF7 cells were subcutaneously inoculated in mice and intratumorally injected with ASO-CTL or ASO-circFOXK2 (5 nm per dose, once every 3 days) 6 times. The growth curve (F), image (G), and weight (H) of the tumor are shown (n=5, ±SD, **P<0.01, ***P<0.001). (I) RNA was extracted from the tumor samples described in (G) and analyzed by RT-qPCR (n=5, ±SD, *P<0.05, **P<0.01, ***P<0.001).

[0025] Figure 5It is shown that the combined treatment of ASO-circFOXK2 and tamoxifen in Example 1 of the present invention showed a synergistic inhibitory effect on the growth of ER-positive breast cancer cells in vitro and in vivo. Wherein: (AC) MCF7 cells were transfected with control ASO (ASO-CTL) or ASO specifically targeting circFOXK2 (ASO-circFOXK2) for 36 hours, and then treated with tamoxifen (5 μM) or without tamoxifen for 36 hours, and then subjected to immunoblotting (A), RT-qPCR (B) and flow cytometry (C) analysis (±SD, *P<0.05, **P<0.01, ***P<0.001). (D) MCF7 cells were transfected with ASO-CTL or ASO-circFOXK2, and then treated with or without tamoxifen (5 μM), and then subjected to cell proliferation assay (±SD, **P<0.01, ***P<0.001). (EG) Mice inoculated subcutaneously with MCF7 cells were treated with ASO-CTL or ASO-circFOXK2 (5 nm per dose, once every 3 days) for 6 times in the presence or absence of tamoxifen (20 mg / kg, once every 3 days). Growth curves (E), images (F), and weights (G) of tumors are shown (n=5, ±SD, **P<0.01, ***P<0.001). (H) RNA extraction and RT-qPCR analysis were performed on the tumor samples described in (F) (n=5, ±SD, *P<0.05, **P<0.01, ***P<0.001). (I) Immunohistochemistry (IHC) analysis of the tumor samples described in (F) was performed with Ki67, CCND1, or p-RB antibodies, and representative images are shown (400x magnification). Scale bar: 50 μm. (J) The mean optical density (OD) of the tumor area in (I) was evaluated using ImageJ software, and the results were expressed as the relative staining intensity compared with the control (n=5, ±SD, *P<0.05, **P<0.01, ***P<0.001).

[0026] Figure 6It shows that ASO-circFOXK2 in Example 1 of the present invention resensitizes tamoxifen-resistant ER-positive breast cancer cells to tamoxifen treatment. Wherein: (AC) Tamoxifen-resistant MCF7 (TamR-MCF7) cells were transfected with control ASO (ASO-CTL) or ASO specifically targeting circFOXK2 (ASO-circFOXK2) for 36 hours, and then treated with or without tamoxifen (5 μM) for 36 hours, and then subjected to immunoblotting (A), RT-qPCR (B) and flow cytometry (C) analysis (±SD, ns: not statistically significant, *P<0.05, **P<0.01, ***P<0.001). (D) TamR-MCF7 cells were transfected with ASO-CTL or ASO-circFOXK2 and treated with or without tamoxifen (5 μM), followed by cell proliferation assay (±SD, ns: not statistically significant, *P<0.05, ***P<0.001). (EG) Female BALB / C nude mice were subcutaneously inoculated with TamR-MCF7 cells and treated with ASO-CTL or ASO-circFOXK2 (5 nm per dose, once every 3 days) for 6 times in the presence or absence of tamoxifen (20 mg / kg, once every 3 days). Growth curves (E), images (F), and weights (G) of tumors are shown (n=5, ±SD, ns: not statistically significant, **P<0.01, ***P<0.001). (H) RNA extraction and RT-qPCR analysis were performed on the tumor samples described in (F) (n=5, ±SD, ns: not statistically significant, *P<0.05, **P<0.01, ***P<0.001). (I) Immunohistochemical analysis of the tumor samples described in (F) was performed with Ki67, CCND1, or p-RB antibodies, and representative images are shown (400-fold magnification). Scale bar: 50 μm. (J) The mean optical density (OD) of the tumor area in (I) was evaluated using ImageJ, and the results are expressed as relative staining intensity compared with the control group (n=5, ±SD, ns: not statistically significant, *P<0.05, **P<0.01, ***P<0.001).

[0027] Figure 7 It shows that circFOXK2 in Example 1 of the present invention is highly expressed in ER-positive breast cancer and other types of cancer and is positively correlated with CCND1. Among them: (A) RT-qPCR analysis of circFOXK2 expression in normal breast epithelial cell lines and different subtypes of breast cancer cell lines (±SD, **P<0.01, ***P<0.001). (B, C) RT-qPCR analysis of ER-positive (ER + , n = 26) or ER negative (ER -, n = 15) Expression of circFOXK2 (B) and CCND1 (C) in breast tumors and adjacent normal breast tissues (±SD, *P < 0.05, **P < 0.01). (DF) Shows the expression of circFOXK2 and CCND1 in breast cancer cell lines (D) and ER + (E) and ER - (F) Correlation of expression in breast tumor tissues. (G, H) RT-qPCR analysis of the expression of circFOXK2 (G) and CCND1 (H) in paired CRC (n = 14), ESCC (n = 14), and PRAD (n = 14) tumors and adjacent normal tissues (±SD, *P < 0.05, **P < 0.01). (I) Shows the expression correlation of circFOXK2 and CCND1 in CRC, ESCC, and PRAD tumor tissues. (J) The proposed model suggests that circFOXK2, which is highly expressed in ER-positive breast cancer cells, directly binds to the 3'UTR of CCND1 mRNA and recruits ELAVL1 to stabilize CCND1 mRNA, leading to CCND1 protein accumulation, uncontrolled G1 / S progression, and ultimately breast tumorigenesis and tamoxifen resistance.

[0028] Figure 8 It shows that circFOXK2 in Example 1 of the present invention promotes the growth of ER-positive breast cancer cells. Wherein: (AC) T47D cells transfected with control siRNA (si-CTL) or two independent siRNAs specifically targeting circFOXK2 (si-circFOXK2-1 and si-circFOXK2-2) were subjected to RT-qPCR (A), cell proliferation (B) and flow cytometry (C) analysis (±SD, ***P<0.001). (DF) MCF7 cells transfected with empty vector (EV) or circFOXK2-expressing vector were subjected to RT-qPCR (D), cell proliferation (E) and flow cytometry (F) analysis (±SD, **P<0.01, ***P<0.001). (G) Figure 1 I shows the body weight of mice.

[0029] Fig. 9It shows that circFOXK2 in Example 1 of the present invention positively regulates the expression of CCND1, activates E2F target genes, and promotes the G1 / S transition of the cell cycle. Wherein: (AC) T47D cells transfected with control siRNA (si-CTL) or two independent siRNAs specifically targeting circFOXK2 (si-circFOXK2-1 and si-circFOXK2-2) were subjected to RT-qPCR (A, C) and immunoblotting (B) analysis (±SD, *P<0.05, **P<0.01, ***P<0.001). (DF) T47D cells transfected with si-CTL or si-circFOXK2 with empty vector (EV) or vector expressing circFOXK2 were subjected to RT-qPCR (D, F) and immunoblotting (E) analysis (±SD, *P<0.05, **P<0.01, ***P<0.001).

[0030] Fig.10 It shows that circFOXK2 in Example 1 of the present invention is stably present in the cytoplasm. Wherein: (A, B) Standard curve for calculating the copy number of circFOXK2 (A) or CCND1 mRNA (B). (C) The copy number of circFOXK2 and CCND1 mRNA in MCF7 cells. (D) Total RNA extracted from MCF7 cells was incubated at 37°C with or without RNase R (10 units / μg RNA) for a duration of time, and RT-qPCR analysis was performed (±SD, ns: no statistical significance, **P<0.01, ***P<0.001). (E) MCF7 cells were treated with actinomycin D (ActD, 10μg / mL) for the indicated time, followed by RT-qPCR analysis (±SD, ns: no statistical significance, ***P<0.001).

[0031] Fig.11 It shows that ASO-circFOXK2 in Example 1 of the present invention inhibits the growth of ER-positive breast cancer cells both in vitro and in vivo. Wherein: (AE) T47D cells transfected with control ASO (ASO-CTL) or ASO specifically targeting circFOXK2 (ASO-circFOXK2) were subjected to RT-qPCR (A, C), immunoblotting (B), flow cytometry cycle (D) and cell proliferation (E) analysis (±SD, *P<0.05, **P<0.01, ***P<0.001). (F) Figure 4 F shows the body weight of mice.

[0032] Fig.12It is shown that the combined treatment of ASO-circFOXK2 and tamoxifen in Example 1 of the present invention showed a synergistic inhibitory effect on the growth of ER-positive breast cancer cells both in vitro and in vivo. Wherein: (AC) T47D cells were transfected with control ASO (ASO-CTL) or ASO specifically targeting circFOXK2 (ASO-circFOXK2) for 36 hours, and then treated with tamoxifen (5 μM) or without tamoxifen for 36 hours, and then subjected to immunoblotting (A), RT-qPCR (B) and flow cytometry (C) analysis (±SD, *P<0.05, **P<0.01, ***P<0.001). (D) T47D cells were transfected with ASO-CTL or ASO-circFOXK2, and treated with or without tamoxifen (5 μM), and cell proliferation assays were performed (±SD, *P<0.05, **P<0.01, ***P<0.001). (E) Figure 5 E: Body weight of mice.

[0033] Fig.13 It shows that ASO-circFOXK2 in Example 1 of the present invention resensitizes ER-positive breast cancer cells resistant to tamoxifen to tamoxifen treatment. Wherein: (A, B) TamR-MCF7 cells were treated with or without tamoxifen (5 μM) as indicated, and then RT-qPCR (A) and immunoblotting (B) analysis were performed (±SD, ns: no statistical significance). (C) TamR-MCF7 cells were transfected with control siRNA (si-CTL) or siRNA specifically targeting CCND1 (si-CCND1) for 36 h, and then tamoxifen (5 μM) was given or not given for 36 h, and flow cytometry cell cycle analysis was performed (±SD, ns: no statistical significance, *P<0.05, ***P<0.001). (D) TamR-MCF7 cells were transfected with si-CTL or si-CCND1 and treated with or without tamoxifen (5 μM), and then subjected to cell proliferation assay (±SD, ns: not statistically significant, *P<0.05, **P<0.01). (E) Figure 6 E: Body weight of mice. DETAILED DESCRIPTION

[0034] The technical solution of the present invention is further illustrated and described below through specific implementation modes in combination with the accompanying drawings.

[0035] Example 1

[0036] 1. Materials and Methods

[0037] Clinical specimens were obtained from breast tumor tissues and matched adjacent normal tissues from patients diagnosed with breast cancer and undergoing surgical treatment at the Second Affiliated Hospital of Shantou University Medical College, approved by the Institutional Ethics Committee of the Second Affiliated Hospital of Shantou University Medical College (ID: 2022-7). Colorectal cancer (CRC) and matched normal tissues were collected from patients with colorectal cancer who underwent surgery at the First Affiliated Hospital of Xiamen University. Esophageal squamous cell carcinoma (ESCC) tissues and matched adjacent normal tissues were obtained from patients diagnosed with ESCC in the Department of Thoracic Surgery, Union Hospital of Fujian Medical University. Prostate tumor (PRAD) tissues and matched adjacent normal tissues were obtained from prostatectomy at Renji Hospital, Shanghai Jiao Tong University School of Medicine, approved by the Institutional Ethics Committee of Renji Hospital, Shanghai Jiao Tong University School of Medicine. Tissue samples were freshly frozen in dry ice and stored at −80°C until RNA extraction. All studies were conducted in compliance with government policies and the Declaration of Helsinki. The experiments were performed with the understanding and written consent of each subject.

[0038] Cell culture Human breast cancer cell lines and embryonic kidney cell line HEK293T were obtained from ATCC and cultured in DMEM supplemented with 10% fetal bovine serum (Biological Industries) and 1% penicillin / streptomycin (Biological Industries). MCF10A cells were obtained from ATCC and cultured in MCF10A medium (Procell) supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin. Tamoxifen-resistant MCF7 (TamR-MCF7) was cultured in DMEM containing 10% fetal bovine serum, 1% penicillin / streptomycin, and 5 μM tamoxifen (MCE). Cells were maintained in a humidified incubator at 37°C with 5% CO2.

[0039] RNA Isolation and RT-qPCR Total RNA was extracted from cells or tissues using TRIzol (Invitrogen) according to the manufacturer's instructions and analyzed using GoScript TM cDNA was synthesized from total RNA using Reverse Transcription Mix and random primers (Promega). qPCR SYBR Green Master Mix (Yeasen) and AriaMx real-time PCR machine (Agilent Technologies) were used for quantitative real-time PCR (RT-qPCR). All RT-qPCR were repeated at least three times, and the relative abundance of each transcript was normalized to the expression level of ACTIN. All primers used for RT-qPCR detection are listed in the table below.

[0040]

[0041]

[0042] Small interfering RNA (siRNA) and antisense oligonucleotide (ASO) transfection siRNA (RiboBio) and ASO (RiboBio) specifically targeting circFOXK2 or siRNA targeting CCND1 were transfected using Lipofectamine 2000 (Invitrogen) reagent according to the manufacturer's instructions. siRNA sequences: ugaaugugcaccuucgggc (si-circFOXK2-1, SEQ ID NO.31), cugaaugugcaccuucggg (si-circFOXK2-2, SEQ ID NO.32) and uucaaugaaaucgugcggg (si-CCND1, SEQ ID NO.33); ASO sequence: aaugugcaccuucgggcugu (ASO-circFOXK2, SEQ ID NO.34). The design of ASO refers to Yi, J. et al. CircPVT1 promotes ER-positivebreast tumorigenesis and drug resistance by targeting ESR1and MAVS. EMBO J 42, e112408, doi: 10.15252 / embj.2022112408 (2023).

[0043] Molecular cloning The shRNA targeting circFOXK2 was cloned into the lentiviral vector pLKO.1 through AgeI and EcoRI restriction endonuclease sites. ShRNA sequences: ugaaugugcaccuucgggcug (sh-circFOXK2-1, SEQ ID NO.35), ccugaaugugcaccuucgggc (sh-circFOXK2-2, SEQ ID NO.36). The full-length circFOXK2 was cloned into the pCD2.1-ciR vector (Geneseed Biotech) through KpnI and BamHI restriction endonuclease sites. The complementary Alu sequence outside the restriction endonuclease sites is responsible for back splicing. The pCD2.1-circFOXK2 plasmid was transfected into cells using Lipo Plus DNA transfection reagent (Sagecreation).

[0044] Lentiviral packaging and infection HEK293T cells were transfected with lentiviral vectors and packaging vectors, pMDL, VSVG, and REV at a ratio of 10:5:3:2 according to the manufacturer's instructions. After 72 h, the viral supernatant was collected through a 0.45 μm filter. The virus was added to MCF7 cells for infection.

[0045] Cell proliferation assay For cell proliferation assays, the CellTiter 96AQueous one solution cell proliferation kit was used to measure cell proliferation. Briefly, cells were treated as indicated and then subjected to cell proliferation assays. Data were recorded using a Thermo Multiskan MK3 microplate reader at a wavelength of 490 nm.

[0046] Flow Cytometry Analysis (FACS) Cells were fixed in 75% cold ethanol at -20°C for at least 24 h and stained with 300-500 μL PI / Triton X-100 staining solution (0.1% (v / v) Triton X-100, 0.2 mg / mL DNase-free RNase A and 0.2 μg / mL PI). Cell cycle distribution was performed on a CytoFLEX LX flow cytometer (Beckman Coulter).

[0047] RNA-seq analysis Total RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. DNase I was added to the column digestion to ensure RNA quality. Ultra TMRNA libraries were prepared using the Directed RNA Library Preparation Kit for Illumina (E7420L) and paired-end sequencing was performed using the Illumina HiSeq 4000 platform. Low-quality reads were cleaned up using two software packages for sequence preprocessing, Fastqc (version 0.11.9) and Fastp (version 0.22.0). The processed reads were aligned to the human reference genome hg38 using STAR (version 2.7.11b). Gene quantification was performed using the SourceForge Subread package featucount (version 2.0.6), with the options -primary (counting only primary alignments), -B (counting only reads aligned at both ends), -C (not counting reads mapped to different chromosomes at both ends or mapped to the same chromosome but on different strands), -q20 (minimum mapping quality score 20), and -s0 (non-stranded). Differential gene analysis was performed using edgeR (version 3.42.4), with FDR < 0.05 and FC ≥ 1.5 as cutoff values. Then, heatmaps and volcano plots were drawn using the pheatmap (version 1.0.12) and ggplot2 (version 3.5.1) packages of R software to depict these differentially expressed genes. GO term analysis was performed using the DAVID bioinformatics website, referring to Sherman, BT et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res 50, W216-W221, doi: 10.1093 / nar / gkac194 (2022). and Huang da, W., Sherman, BT & Lempicki, RA Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57, doi: 10.1038 / nprot.2008.211 (2009).

[0048] Immunoblotting (IB) analysis Wash cells twice with cold PBS, add protease inhibitors and phosphatase inhibitors to lysis buffer (50mM Tris-HCl (pH7.4), 150mM NaCl, 1mM EDTA and 1% Triton X-100), and lyse cells on ice for 30min. The lysate is centrifuged at 20,000g for 10min at 4°C. Protein concentration is determined using the Bio-Rad protein method. Equal amounts of protein samples are boiled in SDS sample buffer, then subjected to SDS-PAGE and transferred to a nitrocellulose membrane (Millipore). Western blotting is performed according to standard protocols. The antibodies used are as follows: rabbit anti-CCND1 polyclonal antibody (Proteintech, 26939-1-AP, 1:2000); rabbit anti-p-RB monoclonal antibody (Ser780) (CST, D59B7, 1:2000); mouse anti-RB monoclonal antibody (Santa Cruz Biotechnology, sc-73598, 1:2000); rabbit anti-CDK4 antibody (Proteintech, 11026-1-AP, 1:2000); rabbit anti-CDK6 antibody (Proteintech, 14052-1-AP, 1:2000); rabbit anti-ELAVL1 monoclonal antibody (Abclonal, A19622, 1:2000); mouse anti-GAPDH monoclonal antibody (Santa Cruz Biotechnology, sc-47724, 1:5000); mouse anti-Flag M2 monoclonal antibody (Sigma, F1804, 1:5000).

[0049] Copy number analysis Copy number analysis was performed according to Castellanos-Rubio, A. et al. A long noncoding RNA associated with susceptibility to celiac disease. Science 352, 91-95, doi: 10.1126 / science.aad0467 (2016). with only minor modifications. Briefly, the cDNA sequence of circFOXK2 or CCND1 was added to the corresponding PCR product to generate a reference standard. Absolute quantification was performed using a 10-fold serial dilution of the standard. Ct versus dilution factor was plotted in a semi-logarithmic plot with a base of 10, and the data were fitted to a straight line. The plot was then used as a standard curve for calculating the copy number of circFOXK2 or CCND1 molecules in cells.

[0050] RNase R digestion Total RNA was treated with RNase R (10 units / μg RNA, Epicentre) in RNase R buffer at 37°C for the durations indicated in the figures and then subjected to RT-qPCR analysis.

[0051] RNA stability assay Cells were continuously treated with 10 μg / mL actinomycin D (MCE). RNA was extracted and analyzed by RT-qPCR.

[0052] Nucleocytoplasmic separation Nucleocytoplasmic separation reference Gao, WW et al. Arginine methylation of HSP70 regulates retinoid acid-mediated RARbeta2 gene activation. Proc Natl Acad Sci USA 112, E3327-3336, doi: 10.1073 / pnas.1509658112 (2015). Briefly, cells were washed with ice-cold PBS, collected, spun, and resuspended in ice-cold buffer I (10 mM Hepes (pH 8.0), 1.5 mM MgCl2, 10 mM KCl, and 1 mM DTT), supplemented with protease inhibitors and RNase inhibitors, and then incubated on ice for 15 min. Igepal-CA630 was added at a final concentration of 1%, vortexed for 10 s, and centrifuged at maximum speed for 3 min to collect cell nuclei. The supernatant obtained was the cytoplasmic fraction. Then, the nuclei were lysed in cold buffer II (20 mM Hepes (pH 8.0), 1.5 mM MgCl2, 25% glycerol, 420 mM NaCl, 0.2 mM EDTA, 1 mM DTT), and protease inhibitors and RNase inhibitors were added, and centrifuged at maximum speed for 15 min. The supernatant obtained was the nuclear fraction. Cytoplasmic and nuclear RNA were extracted using a phenol-chloroform-isoamyl alcohol mixture (Sigma), and then RT-qPCR analysis was performed.

[0053] RNA fluorescence in situ hybridization (RNA-FISH) Cells grown on cell slides were fixed with fixation buffer (4% formaldehyde, 10% acetic acid) for 10 min and permeabilized in 70% ethanol overnight. The cells were then rehydrated in 2×SSC buffer (300 mM NaCl and 30 mM sodium citrate (pH 7.0)) and 50% formamide for 5 min. The hybridization solution containing 30 ng of biotin-labeled DNA probe (Fam-cctgaatgtgcaccttcgggctgtctccac (circFOXK2, SEQ ID NO.37); SangonBiotech) was added to the samples and incubated overnight at 37°C. The cells were washed twice in 2×SSC and 50% formamide solution for 30 min each time. The nuclei were stained with 0.1 μg / mL DAPI. At least three images were taken for each cover glass using a Zeiss laser confocal microscope, and representative images are shown.

[0054] In vitro RNA transcription and circularization In vitro RNA transcription was performed by T7 RNA polymerase (Roche) to generate mRNA from double-stranded DNA templates carrying the T7 promoter sequence system according to the manufacturer's instructions. Briefly, PCR-amplified T7-DNA fragments (200 ng) were incubated with T7 RNA polymerase (2 μL) and dNTP mix or biotin RNA labeling mix (1 mM) at 37°C for 2 h, followed by DNase I treatment at 37°C for 30 min to remove the DNA template. The transcribed RNA was precipitated with ethanol and redissolved in RNase-free water. To circularize the RNA, in vitro transcribed linear RNA (2 μg) was incubated with T4 RNA ligase (ThermoFisher) at 37°C for 4 h, followed by RNase R treatment at 37°C for 2 h to remove the linear RNA. Circular RNA was precipitated with ethanol, resuspended in RNase-free water, and detected by RT-qPCR.

[0055] In vitro RNA-RNA interaction assay The in vitro RNA-RNA interaction assay was performed according to Zhang, Y. et al. Analysis of the androgen receptor-regulated lncRNA landscape identifies arole for ARLNC1 in prostate cancer progression. Nat Genet 50, 814-824, doi: 10.1038 / 111588-018-0120-1 (2018)., with slight modifications. Briefly, biotin-labeled sense or antisense circFOXK2 (5 pmol) was incubated with full-length or binding site-deleted CCND1 3'UTR RNA fragments (2.5 pmol) at 4 °C for 4 h. After incubation, streptavidin C1 Dynabeads (5 μL, Invitrogen) were added to the test tubes respectively and incubated at 4 °C for 2 h. After incubation, the cells were washed six times with RIP buffer (100 mM KCl, 5 mM MgCl2, 10 mM HEPES (pH 7.0), 0.5% NP-40, 1 mM DTT, 2 mM vanadium nucleoside complex solution (Sigma)), and protease inhibitors and RNase inhibitors were added. To recover RNA, the cells were digested with proteinase K buffer supplemented with 1% SDS and 1.2 μg / μL proteinase K (Ambion), and the digestion was rotated at 55°C for 30 min. RNA was isolated using TRIzol and RT-qPCR analysis was performed.

[0056] Chromatin isolation by RNA purification (ChIRP) experiments ChIRP experiments were performed according to Chu, C., Quinn, J. & Chang, HY Chromatin isolation by RNA purification (ChIRP). J VisExp, doi: 10.3791 / 3912 (2012). With minor modifications. Briefly, cells were fixed in 1% formaldehyde, lysed in lysis buffer (50 mM Tris-HCl (pH 7.0), 10 mM EDTA, 1% SDS), and supplemented with 1 mM PMSF, protease inhibitors, and RNase inhibitors. The supernatant was collected, centrifuged at 16100g for 10 min at 4°C, and one volume of supernatant was diluted with two volumes of hybridization buffer (750 mM NaCl, 1% SDS, 50 mM Tris-HCl (pH 7.0), 1 mM EDTA, 15% formamide), and 1 mM PMSF, protease inhibitors and RNase inhibitors were added, and then incubated with 100 pM antisense (biotin-tcgggaacctgaatgtgcaccttcgggctgtctccacctg, SEQ ID NO.38) or sense (biotin-caggtggagacagcccgaaggtgcacattcaggttcccga, SEQ ID NO.39) probes targeting the circFOXK2 reverse splicing site region for 4 h at 37°C with rotation. Then, streptavidin C1 Dynabeads (100 μL per 100 pmol probe) were added to each sample and incubated at 37°C with rotation for 30 min. After incubation, the beads were washed five times with lysis buffer. The beads were then resuspended in RNA PK buffer (100 mM NaCl, 10 mM Tris-HCl (pH 7.0), 1 mM EDTA, and 0.5% SDS) containing 5% proteinase K (20 mg / mL). RNA was isolated using TRIzol and analyzed by RT-qPCR.

[0057] RNA immunoprecipitation (RIP) RIP experiments were performed according to Peritz, T. et al. Immunoprecipitation of mRNA-protein complexes. Nat Protoc 1, 577-580, doi: 10.1038 / nprot.2006.82 (2006). Cells were lysed in a lysis buffer (100 mM KCl, 5 mM MgCl2, 10 mM HEPES (pH 7.0), 0.5% NP-40, 1 mM DTT and 2 mM vanadyl ribonucleoside complex solution) containing protease inhibitors and RNase inhibitors, and then immunoprecipitated (IP) with an anti-ELAVL1 antibody (Abclonal, A19622), washed 4 times with lysis buffer, and washed 4 more times with lysis buffer plus 1 M urea. IP efficiency was detected by SDS-PAGE. 150 μL of buffer containing 0.1% SDS and 45 μg of proteinase K was added and incubated at 50° C. for 30 min to release RNA. Cytoplasmic and nuclear RNA was extracted using a phenol-chloroform-isoamyl alcohol mixture (Sigma) and then subjected to RT-qPCR analysis.

[0058] Xenograft tumor experiments In xenograft experiments, female BALB / C nude mice (4-6 weeks old) were implanted subcutaneously with 5×10 6 MCF7 cells infected with sh-CTL, sh-circFOXK2-1, or sh-circfoxk2-2 suspended in PBS. To evaluate the effects of ASO or tamoxifen, mice were implanted subcutaneously with 5×10 6 MCF7 or TamR-MCF7 cells. After the tumors were palpable, mice were randomly assigned to receive 6 intratumoral injections of ASO-CTL or ASO-circFOXK2 (5 nm per dose, once every 3 days). Mice in the tamoxifen group were gavaged with tamoxifen (20 mg / kg, once every 3 days) 6 times. During the experiment, each nude mouse was brushed with estrogen (E2, 10 -2 M) to maintain the growth of xenograft tumors. Tumors were measured every 3 days, including the long diameter (D) and short diameter (D). The ellipsoid volume formula was used: 1 / 2×D×d 2 Determine the tumor volume. When the tumor reaches 1500mm 3 Mice were sacrificed when the tumor ulcerated / bleeded. The tumors were then excised, photographed, and weighed. Animals were housed at the Experimental Animal Center of Xiamen University under pathogen-free conditions according to protocols approved by the Xiamen Municipal Animal Care and Use Committee.

[0059] Immunohistochemistry (IHC) Immunohistochemistry was performed according to Shen, HF et al. The Dual Function of KDM5C in Both Gene Transcriptional Activation and Repression Promotes Breast Cancer Cell Growth and Tumorigenesis. Adv Sci 8, doi: 10.1002 / advs.202004635 (2021). The antibodies used were as follows: mouse anti-Ki67 monoclonal antibody (Servicebio, GB121141-100, 1:300); rabbit anti-CCND1 polyclonal antibody (Abclonal, A11022, 1:100); rabbit anti-p-RB (Ser780) monoclonal antibody (Abclonal, AP0117, 1:50).

[0060] Statistical Analysis Gene expression data are presented as mean ± SD of at least three independent experiments. Two-tailed Student's t test was used for comparison of two groups or data points. Two-way analysis of variance (ANOVA) was used for multiple comparisons. p value < 0.05 was considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001). GraphPad Prism 9 was used to analyze the xenograft experimental results and clinical specimens.

[0061] 2. Experimental Results

[0062] CircFOXK2 promotes the growth of ER-positive breast cancer cells in vitro and in vivo

[0063] Yi, J. et al. CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS. EMBO J 42, e112408, doi: 10.15252 / embj.2022112408 (2023). reported the expression profile of circRNA in the ER-positive breast cancer cell line MCF7. CircFOXK2 (hsa_circ_0000816) is 343 base pairs (bps) long and is derived from the second and third exons of FOXK2. It plays a key role in promoting cell growth in MCF7 cells ( Figure 1 A). Knockdown of circFOXK2 in MCF7 cells reduces cell growth and induces G1 cell cycle arrest ( Figure 1B-1D). Overexpression of circFOXK2 promoted cell growth and G1 / S phase progression in MCF7 cells ( Figure 1 E-1G). The effects of circFOXK2 on cell growth and cell cycle progression were confirmed in another ER-positive breast cancer cell line, T47D ( Figure 8 A-8F). The oncogenic role of circFOXK2 was further confirmed in a xenograft mouse model. The results showed that knocking out circFOXK2 significantly reduced tumor size ( Figure 1 H-1K) without affecting the body weight of mice ( Figure 8 G). Taken together, these data indicate that circFOXK2 promotes the growth of ER-positive breast cancer cells both in vitro and in vivo.

[0064] CircFOXK2 positively regulates CCND1 expression, activates E2F target genes, and promotes cell cycle G1 / S transition

[0065] In order to clarify the molecular mechanism of circFOXK2 regulating the growth and tumorigenesis of ER-positive breast cancer cells, this example performed gene expression profiling to identify genes regulated by circFOXK2 in MCF7 cells. The results showed that the effects of the two siRNAs targeting circFOXK2 on the entire transcriptome were well correlated (Pearson correlation coefficient = 0.7717) ( Figure 2 A). 712 and 594 genes were positively and negatively regulated by circFOXK2, respectively ( Figure 2 B and Table S1). Gene ontology analysis results showed that circFOXK2 positively regulated genes were related to “cell cycle” ( Figure 2 C and Table S1). Among all these cell cycle genes, CCND1 was one of the most significantly regulated genes and was closely associated with the G1 / S progression of the cell cycle ( Figure 2 D). This example first confirms that in MCF7 ( Figure 2 E and 2F) and T47D cells ( Fig. 9 A and 9B), after circFOXK2 loss, CCND1 expression at both mRNA and protein levels decreased. CCND1-CDK4 / 6 complex phosphorylates RB (p-RB) to release E2F, leading to activation of E2F target genes and G1 / S transition. Downregulation of CCND1 leads to decreased p-RB levels, which in turn leads to downregulation of E2F target genes. This example observed that knocking down circFOXK2 reduced the level of p-RB ( Figure 2F and 9B). In addition, this example found that E2F target genes, such as RBL1, CDC6, MCM6, UHRF1, ERH and PSRC1, were downregulated in MCF7 and T47D cells along with the downregulation of circFOXK2 ( Figure 2 G and 9C). Notably, circFOXK2 knockdown did not affect the expression of CDK4 and CDK6 ( Figure 2 F). In support of the functional importance of these circFOXK2-regulated E2F target genes in tumor development, the expression of these genes was significantly suppressed when circFOXK2 was knocked down in MCF7 cell-derived xenografts ( Figure 1 J and 2H). As expected, in MCF7 and T47D cells, complementation of circFOXK2 in circFOXK2-knockdown cells rescued the decreased CCND1 expression, decreased p-RB levels, and reduced expression of E2F target genes caused by circFOXK2 knockdown in MCF7 cells ( Figure 2 I-2K and 9D-9F).

[0066] In support of circFOXK2 regulating G1 / S transition and cell growth by targeting CCND1, complementation of CCND1 rescued the decreased p-RB level and reduced expression of E2F target genes caused by circFOXK2 knockdown in MCF7 cells ( Figure 2 L and 2M). Moreover, the introduction of CCND1 rescued the cell cycle and growth defects caused by circFOXK2 knockdown ( Figure 2 N and 2O). Taken together, these data indicate that circFOXK2 regulates CCND1 expression and promotes the G1 / S transition in the cell cycle.

[0067] CircFOXK2 interacts with the 3'UTR of CCND1 mRNA and recruits ELAVL1 to stabilize CCND1 mRNA

[0068] In order to further explore how circFOXK2 regulates the expression of CCND1, this example first detected the localization of circFOXK2 by nuclear-cytoplasmic separation and FISH experiments. The results showed that it was mainly located in the cytoplasm ( Figure 3A and 3B). One of the general mechanisms by which cytoplasmic circRNAs regulate mRNA abundance is to act as competitive endogenous RNAs (ceRNAs), thereby competing with mRNAs for binding to miRNAs. Therefore, this example constructed a ceRNA network for circFOXK2, but did not predict miRNAs that target both circFOXK2 and CCND1. Another way that noncoding RNAs regulate mRNA biology is through direct RNA-RNA interactions. By intraRNA site analysis, the 3'UTR of CCND1 (nucleotides 2878-2963) was predicted to be able to pair with circFOXK2 (nucleotides 120-217) ( Figure 3 C). In vitro RNA-RNA interaction assay confirmed the direct interaction between circFOXK2 and the 3'UTR of CCND1 ( Figure 3 D). Deletion of nucleotides 120-217 in circFOXK2 significantly reduced the interaction between circFOXK2 and the 3'UTR of CCND1 ( Figure 3 D). To further demonstrate the interaction between circFOXK2 and CCND1, this example performed ChIRP-qPCR detection in MCF7 cells using an antisense probe specifically targeting the splicing site (BSJ) of circFOXK2. The results showed that CCND1 bound to circFOXK2, while GAS5 did not ( Figure 3 E). As negative controls, circFOXK2, CCND1, or GAS5 were not pulled down by the sense probe of circFOXK2.

[0069] Next, the goal of this example is to explore how the direct interaction between circFOXK2 and CCND1 regulates the expression of CCND1. It has been reported that the RNA binding protein (RBP) ELAVL1 / HuR can selectively bind to AU-rich sequences in the 3'UTR of mRNA and stabilize mRNA. The CircInteractome database shows that circFOXK2 has three ELAVL1 binding sites ( Figure 3 C). In addition, ELAVL1 has been shown to bind to CCND1 mRNA by photoactivation-ribonucleoside enhanced cross-linking and immunoprecipitation (PAR-CLIP) experiments. Therefore, this example first tested whether circFOXK2 binds to ELAVL1 by ChIRP-immunoblotting analysis. The results showed that ELAVL1 was pulled down by the antisense probe targeting circFOXK2, but not the sense probe ( Figure 3 F). RNA immunoprecipitation (RIP) experiments with anti-ELAVL1 specific antibodies showed that ELAVL1 bound to circFOXK2 and CCND1 ( Figure 3G and 3H). Interestingly, the enrichment of CCND1 was significantly reduced after circFOXK2 knockdown in MCF7 cells ( Figure 3 H). However, the enrichment of CCNB1, a gene encoding a cell cycle protein reported to bind to ELAVL1, was not altered by knockdown of circFOXK2 ( Figure 3 H). As a negative control, GAPDH mRNA did not bind to ELAVL1 ( Figure 3 H). Therefore, this example proposes that circFOXK2 recruits ELAVL1 to stabilize CCND1 mRNA. To verify this, this example treated control and circFOXK2 knockdown MCF7 cells with actinomycin D (ActD) to inhibit transcription, and then tested the stability of mRNA. The results showed that after circFOXK2 knockdown, the stability of CCND1 mRNA was significantly reduced ( Figure 3 I). As a negative control, the stability of ACTIN mRNA was not affected ( Figure 3 I). The copy number of circFOXK2 in MCF7 cells is comparable to that of CCND1 ( Fig.10 A-10C). In addition, similar to other circRNAs, circFOXK2 was much more stable than its parental gene FOXK2 in the presence of RNase R and ActD ( Fig.10 D and 10E). To further support that circFOXK2 can stabilize CCND1 mRNA, the expression of Flag-tagged CCND1-3'UTR (WT), but not CCND1-3'UTR (Δ2878-2963), was significantly increased at both RNA and protein levels in the presence of circFOXK2 ( Figure 3 J and 3K). Taken together, these data indicate that circFOXK2 directly binds to the 3'UTR of CCND1 mRNA and recruits ELAVL1 to stabilize CCND1 mRNA.

[0070] Antisense oligonucleotides targeting circFOXK2 (ASO-circFOXK2) inhibit the growth of ER-positive breast cancer cells in vitro and in vivo

[0071] The functional importance of circFOXK2 prompted this study to explore its potential as a therapeutic target for ER-positive breast cancer. ASOs can modulate gene expression by blocking translation or promoting RNA degradation and have been used in research and therapy. Therefore, this study designed an ASO drug targeting the splicing site of circFOXK2 (ASO-circFOXK2), which can effectively reduce circFOXK2 in MCF7 and T47D cells ( Figure 4A and 11A). In MCF7 cells treated with ASO-circFOXK2, CCND1 mRNA and protein levels, p-RB levels, and the expression of E2F target genes were significantly decreased ( Figure 4 B, 4C, 11B, and 11C). Therefore, ASO-circFOXK2 treatment resulted in cell arrest in the G1 phase and decreased cell proliferation rate ( Figure 4 D, 4E, 11D and 11E). In addition, ASO-circFOXK2 significantly inhibited the growth of MCF7 cell-derived tumors ( Figure 4 F-4H) without affecting the body weight of mice ( Fig.11 F). Meanwhile, the expression of CCND1 and E2F target genes was downregulated in ASO-circFOXK2-treated tumors ( Figure 4 I). Taken together, these data indicate that ASO targeting circFOXK2 can effectively inhibit the growth of ER-positive breast cancer cells both in vitro and in vivo.

[0072] Combination therapy of ASO-circFOXK2 and tamoxifen exhibits synergistic inhibitory effects on the growth of ER-positive breast cancer cells both in vitro and in vivo

[0073] Endocrine therapy is one of the most effective treatment options for estrogen receptor-positive breast cancer. However, some patients still have primary resistance to this therapy. Since CCND1 itself and its downstream E2F target gene are the main targets of tamoxifen, this example examined whether ASO-circFOXK2 treatment would increase tamoxifen sensitivity in MCF7 cells. As expected, ASO-circFOXK2 and tamoxifen treatment reduced CCND1 expression, RB phosphorylation, and E2F target gene expression in MCF7 and T47D cells, respectively ( Figure 5 Interestingly, the combination of ASO-circFOXK2 and tamoxifen had the most significant inhibition on CCND1 expression, RB phosphorylation, and E2F target gene expression ( Figure 5 A, 5B, 12A, and 12B). Therefore, the results of cell cycle and cell proliferation analysis indicated that the combination of ASO-circFOXK2 and tamoxifen had a synergistic effect in inhibiting G1 / S progression and cell growth compared with ASO-circFOXK2 or tamoxifen treatment alone in MCF7 and T47D cells ( Figure 5 C, 5D, 12C, and 12D). More importantly, ASO-circFOXK2 further enhanced the inhibitory effect of tamoxifen on tumor growth in an MCF7 cell-derived xenograft mouse model ( Figure 5 E-5G, without affecting the body weight of mice ( Fig.12E). As expected, CCND1 and E2F target genes were least expressed in tumors co-treated with ASO-circFOXK2 and tamoxifen ( Figure 5 H). Immunohistochemical (IHC) staining of tumor tissue sections further showed that ASO-circFOXK2 combined with tamoxifen had a synergistic effect in reducing Ki67 and CCND1 expression and p-RB abundance ( Figure 5 I and 5J). Taken together, these data suggest that ASO-circFOXK2 and tamoxifen have a synergistic tumor suppressor effect.

[0074] ASO-circFOXK2 resensitizes tamoxifen-resistant ER-positive breast cancer cells to tamoxifen treatment

[0075] In the treatment of ER-positive breast cancer, uncontrolled abnormal expression of CCND1 is associated with endocrine therapy resistance. Therefore, this example proposes that targeting circFOXK2 may effectively overcome endocrine therapy resistance in estrogen receptor-positive breast cancer. This example first confirmed that CCND1 is no longer regulated by tamoxifen in tamoxifen-resistant MCF7 cells (TamR-MCF7) ( Fig.13 A and 13B), which is significantly different from the parental MCF7 cells ( Figure 5 A and 5B). In addition, CCND1 knockdown restored the sensitivity of TamR-MCF7 cells to tamoxifen, as shown by tamoxifen arresting cells in G1 and significantly slowing down cell growth after CCND1 knockdown ( Fig.13 C and 13D). Then, this example examined whether ASO-circFOXK2 could restore the sensitivity of TamR-MCF7 cells to tamoxifen. As expected, tamoxifen had no effect on CCND1 expression, RB phosphorylation, or the expression of E2F target genes regulated by circFOXK2 in TamR-MCF7 cells ( Figure 6 A and 6B). Therefore, tamoxifen treatment did not affect G1 / S progression and cell growth ( Figure 6 C and 6D). However, ASO-circFOXK2 resensitized TamR-MCF7 cells to tamoxifen treatment, as shown by the significant reduction of CCND1 and E2F target gene expression, reduced RB phosphorylation, slower G1 / S progression, and slower cell growth after ASO-circDOXK2 treatment of cells ( Figure 6 A-6D).

[0076] In addition, this example explored whether targeting circFOXK2 would restore tamoxifen sensitivity in a xenograft mouse model. TamR-MCF7 cells were subcutaneously inoculated into female BALB / C nude mice and then treated with ASO and / or tamoxifen. Consistent with the results observed in the cell experiments of this example, ASO-circFOXK2 treatment restored the sensitivity of TamR-MCF7 cell-derived xenografts to tamoxifen, resulting in a significant decrease in tumor growth ( Figure 6 E-6G). The body weight of mice was not affected ( Fig.13 E). RT-qPCR and immunohistochemistry analysis of tumor tissues showed that ASO-circFOXK2 treatment restored the sensitivity of CCND1 expression, RB phosphorylation, circFOXK2-regulated E2F target gene expression, and Ki67 expression to tamoxifen treatment ( Figure 6 H-6J). Taken together, these data suggest that ASO targeting circFOXK2 can effectively overcome tamoxifen resistance in ER-positive breast cancer cells.

[0077] CircFOXK2 is highly expressed in ER-positive breast cancer and other cancer types and positively correlates with CCND1 expression

[0078] To investigate the clinical relevance of circFOXK2 in regulating CCND1, this example first detected the expression of circFOXK2 in various breast cancer cell lines. This example found that compared with the normal breast epithelial cell line MCF10A, the expression of circFOXK2 in ER-positive breast cancer cell lines (including T47D, HCC1500, and MCF7) was significantly higher ( Figure 7 A). Notably, it is also highly expressed in Her2-positive and triple-negative breast cancer (TNBC) cell lines ( Figure 7 A). In addition, circFOXK2 was significantly upregulated in both clinical ER-positive and ER-negative breast tumors compared with normal adjacent tissues ( Figure 7 B). As expected, CCND1 is also highly expressed in breast tumor samples ( Figure 7 C). More importantly, the expression of circFOXK2 was positively correlated with CCND1 in breast cancer cell lines and clinical breast tumor tissues ( Figure 7 D-7F). A large number of studies have shown that CCND1 is overexpressed and / or amplified in a variety of tumors, thus causing cancer. Therefore, this example detects the expression of circFOXK2 and CCND1 and their correlation in other cancer types. The results showed that circFOXK2 and CCND1 were significantly expressed in a variety of cancer types detected in this example, including colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC) and prostate cancer (PRAD) ( Figure 7 G and 7H). More importantly, the expression of circFOXK2 was highly positively correlated with the expression of CCND1 ( Figure 7 I). Taken together, these data suggest that circFOXK2 is highly expressed and positively correlated with CCND1 in breast cancer and other cancer types.

[0079] The above description is only a preferred embodiment of the present invention, and therefore cannot be used to limit the scope of the present invention. That is, equivalent changes and modifications made according to the patent scope of the present invention and the contents of the specification should still fall within the scope of the present invention.

Claims

1. An antisense oligonucleotide targeting circFOXK2, characterized in that: Its nucleotide sequence is shown in SEQ ID NO.

34.

2. Use of the antisense oligonucleotide according to claim 1 in preparing a composition for inhibiting the growth of ER-positive breast cancer cells.

3. The use according to claim 2, characterized in that: The ER-positive breast cancer cell growth inhibition composition also contains tamoxifen.

4. An ER-positive breast cancer cell growth inhibition composition, characterized in that: The effective component thereof comprises the antisense oligonucleotide according to claim 1.

5. The ER-positive breast cancer cell growth inhibition composition according to claim 4, characterized in that: Its active ingredient also includes tamoxifen.

6. Use of the antisense oligonucleotide according to claim 1 in preparing a composition for treating ER-positive breast cancer.

7. The use according to claim 6, characterized in that: The ER-positive breast cancer treatment composition also contains tamoxifen.

8. A composition for treating ER-positive breast cancer, characterized in that: The effective component thereof comprises the antisense oligonucleotide according to claim 1.

9. The composition for treating ER-positive breast cancer according to claim 8, characterized in that: Its active ingredient also includes tamoxifen.

10. The composition for treating ER-positive breast cancer according to claim 9, characterized in that: The effective ingredients are composed of the antisense oligonucleotide and tamoxifen.